ID   PDE4D_HUMAN             Reviewed;         809 AA.
AC   Q08499; O43433; Q13549; Q13550; Q13551; Q7Z2L8; Q8IV84; Q8IVA9;
AC   Q8IVD2; Q8IVD3; Q96HL4; Q9HCX7;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2000, sequence version 2.
DT   22-JUL-2015, entry version 169.
DE   RecName: Full=cAMP-specific 3',5'-cyclic phosphodiesterase 4D;
DE            EC=3.1.4.53;
DE   AltName: Full=DPDE3;
DE   AltName: Full=PDE43;
GN   Name=PDE4D; Synonyms=DPDE3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3 AND 4).
RX   PubMed=8413254;
RA   Bolger G., Michaeli T., Martins T., St John T., Steiner B.,
RA   Rodgers L., Riggs M., Wigler M., Ferguson K.;
RT   "A family of human phosphodiesterases homologous to the dunce learning
RT   and memory gene product of Drosophila melanogaster are potential
RT   targets for antidepressant drugs.";
RL   Mol. Cell. Biol. 13:6558-6571(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 4).
RX   PubMed=8797812; DOI=10.1016/0014-5793(96)00300-6;
RA   Nemoz G., Zhang R.B., Sette C., Conti M.;
RT   "Identification of cyclic AMP-phosphodiesterase variants from the
RT   PDE4D gene expressed in human peripheral mononuclear cells.";
RL   FEBS Lett. 384:97-102(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 10).
RC   TISSUE=Heart;
RX   PubMed=8125310; DOI=10.1016/0378-1119(94)90818-4;
RA   Baecker P.A., Obernolte R., Bach C., Yee C., Shelton E.R.;
RT   "Isolation of a cDNA encoding a human rolipram-sensitive cyclic AMP
RT   phosphodiesterase (PDE IVD).";
RL   Gene 138:253-256(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 4; 5 AND 10), AND
RP   SEQUENCE REVISION (ISOFORM 1).
RX   PubMed=9371713;
RA   Bolger G.B., Erdogan S., Jones R.E., Loughney K., Scotland G.,
RA   Hoffmann R., Wilkinson I., Farrell C., Houslay M.D.;
RT   "Characterization of five different proteins produced by alternatively
RT   spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D
RT   gene.";
RL   Biochem. J. 328:539-548(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM N3), AND ALTERNATIVE SPLICING.
RC   TISSUE=Umbilical vein endothelial cell;
RX   PubMed=10913353; DOI=10.1006/bbrc.2000.3146;
RA   Miro X., Casacuberta J.M., Gutierrez-Lopez M.D., Landazuri M.O.,
RA   Puigdomenech P.;
RT   "Phosphodiesterases 4D and 7A splice variants in the response of HUVEC
RT   cells to TNF-alpha1.";
RL   Biochem. Biophys. Res. Commun. 274:415-421(2000).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 6; 7; 8 AND 9), PHOSPHORYLATION,
RP   AND TISSUE SPECIFICITY.
RX   PubMed=12834813; DOI=10.1016/S0898-6568(03)00042-1;
RA   Wang D., Deng C., Bugaj-Gaweda B., Kwan M., Gunwaldsen C., Leonard C.,
RA   Xin X., Hu Y., Unterbeck A., De Vivo M.;
RT   "Cloning and characterization of novel PDE4D isoforms PDE4D6 and
RT   PDE4D7.";
RL   Cell. Signal. 15:883-891(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 7 AND 9), AND INVOLVEMENT IN
RP   SUSCEPTIBILITY TO STROKE.
RX   PubMed=14517540; DOI=10.1038/ng1245;
RA   Gretarsdottir S., Thorleifsson G., Reynisdottir S.T., Manolescu A.,
RA   Jonsdottir S., Jonsdottir T., Gudmundsdottir T., Bjarnadottir S.M.,
RA   Einarsson O.B., Gudjonsdottir H.M., Hawkins M., Gudmundsson G.,
RA   Gudmundsdottir H., Andrason H., Gudmundsdottir A.S.,
RA   Sigurdardottir M., Chou T.T., Nahmias J., Goss S.,
RA   Sveinbjoernsdottir S., Valdimarsson E.M., Jakobsson F., Agnarsson U.,
RA   Gudnason V., Thorgeirsson G., Fingerle J., Gurney M., Gudbjartsson D.,
RA   Frigge M.L., Kong A., Stefansson K., Gulcher J.R.;
RT   "The gene encoding phosphodiesterase 4D confers risk of ischemic
RT   stroke.";
RL   Nat. Genet. 35:131-138(2003).
RN   [8]
RP   ERRATUM.
RA   Gretarsdottir S., Thorleifsson G., Reynisdottir S.T., Manolescu A.,
RA   Jonsdottir S., Jonsdottir T., Gudmundsdottir T., Bjarnadottir S.M.,
RA   Einarsson O.B., Gudjonsdottir H.M., Hawkins M., Gudmundsson G.,
RA   Gudmundsdottir H., Andrason H., Gudmundsdottir A.S.,
RA   Sigurdardottir M., Chou T.T., Nahmias J., Goss S.,
RA   Sveinbjoernsdottir S., Valdimarsson E.M., Jakobsson F., Agnarsson U.,
RA   Gudnason V., Thorgeirsson G., Fingerle J., Gurney M., Gudbjartsson D.,
RA   Frigge M.L., Kong A., Stefansson K., Gulcher J.R.;
RL   Nat. Genet. 37:555-555(2005).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 12).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 6 AND 12).
RC   TISSUE=Brain, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   INTERACTION WITH GNB2L1.
RX   PubMed=12193273; DOI=10.1186/1471-2091-3-24;
RA   Bolger G.B., McCahill A., Yarwood S.J., Steele M.S., Warwicker J.,
RA   Houslay M.D.;
RT   "Delineation of RAID1, the RACK1 interaction domain located within the
RT   unique N-terminal region of the cAMP-specific phosphodiesterase,
RT   PDE4D5.";
RL   BMC Biochem. 3:24-24(2002).
RN   [12]
RP   INTERACTION WITH ARRB2, AND SUBCELLULAR LOCATION.
RX   PubMed=14500724; DOI=10.1074/jbc.M303772200;
RA   Bolger G.B., McCahill A., Huston E., Cheung Y.F., McSorley T.,
RA   Baillie G.S., Houslay M.D.;
RT   "The unique amino-terminal region of the PDE4D5 cAMP phosphodiesterase
RT   isoform confers preferential interaction with beta-arrestins.";
RL   J. Biol. Chem. 278:49230-49238(2003).
RN   [13]
RP   HOMODIMERIZATION OF LONG ISOFORMS, ENZYME REGULATION BY ROLIPRAM AND
RP   PHOSPHATIDIC ACID, AND PHOSPHORYLATION AT SER-53 (ISOFORM 3).
RX   PubMed=15131123; DOI=10.1074/jbc.M312687200;
RA   Richter W., Conti M.;
RT   "The oligomerization state determines regulatory properties and
RT   inhibitor sensitivity of type 4 cAMP-specific phosphodiesterases.";
RL   J. Biol. Chem. 279:30338-30348(2004).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [15]
RP   DISCUSSION OF INVOLVEMENT IN STROKE.
RX   PubMed=17006457; DOI=10.1038/ng1006-1091;
RA   Rosand J., Bayley N., Rost N., de Bakker P.I.W.;
RT   "Many hypotheses but no replication for the association between PDE4D
RT   and stroke.";
RL   Nat. Genet. 38:1091-1092(2006).
RN   [16]
RP   INTERACTION WITH SHANK2, AND TISSUE SPECIFICITY.
RX   PubMed=17244609; DOI=10.1074/jbc.M610857200;
RA   Lee J.H., Richter W., Namkung W., Kim K.H., Kim E., Conti M.,
RA   Lee M.G.;
RT   "Dynamic regulation of cystic fibrosis transmembrane conductance
RT   regulator by competitive interactions of molecular adaptors.";
RL   J. Biol. Chem. 282:10414-10422(2007).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-59 AND SER-63 (ISOFORMS
RP   12; 5 AND N3), AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [19]
RP   SUMOYLATION AT LYS-387 BY PIAS4.
RX   PubMed=20196770; DOI=10.1042/BJ20091672;
RA   Li X., Vadrevu S., Dunlop A., Day J., Advant N., Troeger J.,
RA   Klussmann E., Jaffrey E., Hay R.T., Adams D.R., Houslay M.D.,
RA   Baillie G.S.;
RT   "Selective SUMO modification of cAMP-specific phosphodiesterase-4D5
RT   (PDE4D5) regulates the functional consequences of phosphorylation by
RT   PKA and ERK.";
RL   Biochem. J. 428:55-65(2010).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-299 AND SER-301, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 388-715 IN COMPLEX WITH THE
RP   INHIBITOR ZARDAVERINE AND DIVALENT METAL IONS, AND MUTAGENESIS OF
RP   ASP-527 AND ARG-563.
RX   PubMed=12387865; DOI=10.1016/S0014-5793(02)03396-3;
RA   Lee M.E., Markowitz J., Lee J.-O., Lee H.;
RT   "Crystal structure of phosphodiesterase 4D and inhibitor complex.";
RL   FEBS Lett. 530:53-58(2002).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 381-739 IN COMPLEX WITH CAMP
RP   AND DIVALENT METAL IONS.
RX   PubMed=14609333; DOI=10.1021/bi034653e;
RA   Huai Q., Colicelli J., Ke H.;
RT   "The crystal structure of AMP-bound PDE4 suggests a mechanism for
RT   phosphodiesterase catalysis.";
RL   Biochemistry 42:13220-13226(2003).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 381-739 IN COMPLEX WITH
RP   INHIBITOR.
RX   PubMed=12842049; DOI=10.1016/S0969-2126(03)00123-0;
RA   Huai Q., Wang H., Sun Y., Kim H.Y., Liu Y., Ke H.;
RT   "Three-dimensional structures of PDE4D in complex with roliprams and
RT   implication on inhibitor selectivity.";
RL   Structure 11:865-873(2003).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 381-714 IN COMPLEX WITH METAL
RP   IONS AND INHIBITOR.
RX   PubMed=14668322; DOI=10.1074/jbc.M311556200;
RA   Huai Q., Liu Y., Francis S.H., Corbin J.D., Ke H.;
RT   "Crystal structures of phosphodiesterases 4 and 5 in complex with
RT   inhibitor 3-isobutyl-1-methylxanthine suggest a conformation
RT   determinant of inhibitor selectivity.";
RL   J. Biol. Chem. 279:13095-13101(2004).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 380-756 IN COMPLEX WITH AMP;
RP   METAL IONS AND THE INHIBITOR ROLIPRAM.
RX   PubMed=15003452; DOI=10.1016/j.jmb.2004.01.040;
RA   Xu R.X., Rocque W.J., Lambert M.H., Vanderwall D.E., Luther M.A.,
RA   Nolte R.T.;
RT   "Crystal structures of the catalytic domain of phosphodiesterase 4B
RT   complexed with AMP, 8-Br-AMP, and rolipram.";
RL   J. Mol. Biol. 337:355-365(2004).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 388-715 IN COMPLEX WITH AMP;
RP   METAL IONS AND THE INHIBITOR ROLIPRAM, FUNCTION, AND COFACTOR.
RX   PubMed=15260978; DOI=10.1016/j.molcel.2004.07.005;
RA   Zhang K.Y.J., Card G.L., Suzuki Y., Artis D.R., Fong D., Gillette S.,
RA   Hsieh D., Neiman J., West B.L., Zhang C., Milburn M.V., Kim S.-H.,
RA   Schlessinger J., Bollag G.;
RT   "A glutamine switch mechanism for nucleotide selectivity by
RT   phosphodiesterases.";
RL   Mol. Cell 15:279-286(2004).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (1.54 ANGSTROMS) OF 388-715 IN COMPLEX WITH
RP   METAL IONS AND INHIBITORS, FUNCTION, AND COFACTOR.
RX   PubMed=15576036; DOI=10.1016/j.str.2004.10.004;
RA   Card G.L., England B.P., Suzuki Y., Fong D., Powell B., Lee B.,
RA   Luu C., Tabrizizad M., Gillette S., Ibrahim P.N., Artis D.R.,
RA   Bollag G., Milburn M.V., Kim S.-H., Schlessinger J., Zhang K.Y.J.;
RT   "Structural basis for the activity of drugs that inhibit
RT   phosphodiesterases.";
RL   Structure 12:2233-2247(2004).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (1.36 ANGSTROMS) OF 388-715 IN COMPLEX WITH
RP   METAL IONS AND INHIBITORS.
RX   PubMed=15685167; DOI=10.1038/nbt1059;
RA   Card G.L., Blasdel L., England B.P., Zhang C., Suzuki Y., Gillette S.,
RA   Fong D., Ibrahim P.N., Artis D.R., Bollag G., Milburn M.V., Kim S.-H.,
RA   Schlessinger J., Zhang K.Y.J.;
RT   "A family of phosphodiesterase inhibitors discovered by
RT   cocrystallography and scaffold-based drug design.";
RL   Nat. Biotechnol. 23:201-207(2005).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 381-741 IN COMPLEX WITH
RP   METAL IONS AND INHIBITORS.
RX   PubMed=16539372; DOI=10.1021/jm051273d;
RA   Huai Q., Sun Y., Wang H., Macdonald D., Aspiotis R., Robinson H.,
RA   Huang Z., Ke H.;
RT   "Enantiomer discrimination illustrated by the high resolution crystal
RT   structures of type 4 phosphodiesterase.";
RL   J. Med. Chem. 49:1867-1873(2006).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (1.57 ANGSTROMS) OF 388-715 IN COMPLEX WITH
RP   METAL IONS AND THE INHIBITOR NVP.
RX   PubMed=17727341; DOI=10.1042/BJ20070970;
RA   Wang H., Peng M.-S., Chen Y., Geng J., Robinson H., Houslay M.D.,
RA   Cai J., Ke H.;
RT   "Structures of the four subfamilies of phosphodiesterase-4 provide
RT   insight into the selectivity of their inhibitors.";
RL   Biochem. J. 408:193-201(2007).
RN   [32]
RP   STRUCTURE BY NMR OF N-TERMINUS OF ISOFORM 5/N3/12, AND INTERACTION
RP   WITH GNB2L1.
RX   PubMed=17900862; DOI=10.1016/j.cellsig.2007.08.015;
RA   Smith K.J., Baillie G.S., Hyde E.I., Li X., Houslay T.M., McCahill A.,
RA   Dunlop A.J., Bolger G.B., Klussmann E., Adams D.R., Houslay M.D.;
RT   "1H NMR structural and functional characterisation of a cAMP-specific
RT   phosphodiesterase-4D5 (PDE4D5) N-terminal region peptide that disrupts
RT   PDE4D5 interaction with the signalling scaffold proteins, beta-
RT   arrestin and RACK1.";
RL   Cell. Signal. 19:2612-2624(2007).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (1.56 ANGSTROMS) OF 388-714 OF MUTANT ASN-503 IN
RP   COMPLEX WITH CAMP AND METAL IONS.
RX   PubMed=17582435; DOI=10.1016/j.jmb.2007.05.060;
RA   Wang H., Robinson H., Ke H.;
RT   "The molecular basis for different recognition of substrates by
RT   phosphodiesterase families 4 and 10.";
RL   J. Mol. Biol. 371:302-307(2007).
RN   [34]
RP   VARIANTS ACRDYS2 ALA-190; THR-225; SER-226 AND PRO-587.
RX   PubMed=22464250; DOI=10.1016/j.ajhg.2012.03.003;
RA   Michot C., Le Goff C., Goldenberg A., Abhyankar A., Klein C.,
RA   Kinning E., Guerrot A.M., Flahaut P., Duncombe A., Baujat G.,
RA   Lyonnet S., Thalassinos C., Nitschke P., Casanova J.L., Le Merrer M.,
RA   Munnich A., Cormier-Daire V.;
RT   "Exome sequencing identifies PDE4D mutations as another cause of
RT   acrodysostosis.";
RL   Am. J. Hum. Genet. 90:740-745(2012).
RN   [35]
RP   VARIANTS ACRDYS2 GLU-228; ALA-590 AND ASP-673.
RX   PubMed=22464252; DOI=10.1016/j.ajhg.2012.03.004;
RA   Lee H., Graham J.M. Jr., Rimoin D.L., Lachman R.S., Krejci P.,
RA   Tompson S.W., Nelson S.F., Krakow D., Cohn D.H.;
RT   "Exome sequencing identifies PDE4D mutations in acrodysostosis.";
RL   Am. J. Hum. Genet. 90:746-751(2012).
RN   [36]
RP   VARIANTS ACRDYS2 SER-227 AND ALA-590.
RX   PubMed=23043190; DOI=10.1210/jc.2012-2326;
RA   Linglart A., Fryssira H., Hiort O., Holterhus P.M.,
RA   Perez de Nanclares G., Argente J., Heinrichs C., Kuechler A.,
RA   Mantovani G., Leheup B., Wicart P., Chassot V., Schmidt D.,
RA   Rubio-Cabezas O., Richter-Unruh A., Berrade S., Pereda A., Boros E.,
RA   Munoz-Calvo M.T., Castori M., Gunes Y., Bertrand G., Bougneres P.,
RA   Clauser E., Silve C.;
RT   "PRKAR1A and PDE4D mutations cause acrodysostosis but two distinct
RT   syndromes with or without GPCR-signaling hormone resistance.";
RL   J. Clin. Endocrinol. Metab. 97:E2328-E2338(2012).
RN   [37]
RP   VARIANTS ACRDYS2 THR-225; THR-301; VAL-304; ALA-329 AND THR-678.
RX   PubMed=23033274; DOI=10.1002/humu.22222;
RG   FORGE Canada Consortium;
RA   Lynch D.C., Dyment D.A., Huang L., Nikkel S.M., Lacombe D.,
RA   Campeau P.M., Lee B., Bacino C.A., Michaud J.L., Bernier F.P.,
RA   Parboosingh J.S., Innes A.M.;
RT   "Identification of novel mutations confirms Pde4d as a major gene
RT   causing acrodysostosis.";
RL   Hum. Mutat. 34:97-102(2013).
CC   -!- FUNCTION: Hydrolyzes the second messenger cAMP, which is a key
CC       regulator of many important physiological processes.
CC       {ECO:0000269|PubMed:15260978, ECO:0000269|PubMed:15576036}.
CC   -!- CATALYTIC ACTIVITY: Adenosine 3',5'-cyclic phosphate + H(2)O =
CC       adenosine 5'-phosphate.
CC   -!- COFACTOR:
CC       Name=a divalent metal cation; Xref=ChEBI:CHEBI:60240;
CC         Evidence={ECO:0000269|PubMed:15260978,
CC         ECO:0000269|PubMed:15576036};
CC       Note=Binds 2 divalent metal cations per subunit. Site 1 may
CC       preferentially bind zinc ions, while site 2 has a preference for
CC       magnesium and/or manganese ions. {ECO:0000269|PubMed:15260978,
CC       ECO:0000269|PubMed:15576036};
CC   -!- ENZYME REGULATION: Inhibited by rolipram. Activated by
CC       phosphatidic acid. {ECO:0000269|PubMed:15131123}.
CC   -!- PATHWAY: Purine metabolism; 3',5'-cyclic AMP degradation; AMP from
CC       3',5'-cyclic AMP: step 1/1.
CC   -!- SUBUNIT: Homodimer for the long isoforms. Isoforms with truncated
CC       N-termini are monomeric. Isoform 3 is part of a ternary complex
CC       containing PRKAR2A, PRKAR2B and AKAP9. Interacts with PDE4DIP.
CC       Identified in a complex composed of RYR1, PDE4D, PKA, FKBP1A and
CC       protein phosphatase 1 (PP1) (By similarity). Isoform 5, isoform N3
CC       and isoform 12 bind GNB2L1 via their unique N-terminus. Binds
CC       ARRB2. Interacts (via N-terminal region) with SHANK2 (via proline-
CC       rich region); the interaction is increased in a PKA-dependent
CC       manner. {ECO:0000250, ECO:0000269|PubMed:12193273,
CC       ECO:0000269|PubMed:12387865, ECO:0000269|PubMed:12842049,
CC       ECO:0000269|PubMed:14500724, ECO:0000269|PubMed:14609333,
CC       ECO:0000269|PubMed:14668322, ECO:0000269|PubMed:15003452,
CC       ECO:0000269|PubMed:15260978, ECO:0000269|PubMed:15576036,
CC       ECO:0000269|PubMed:15685167, ECO:0000269|PubMed:16539372,
CC       ECO:0000269|PubMed:17244609, ECO:0000269|PubMed:17582435,
CC       ECO:0000269|PubMed:17727341, ECO:0000269|PubMed:17900862}.
CC   -!- INTERACTION:
CC       P26769:Adcy2 (xeno); NbExp=3; IntAct=EBI-8095525, EBI-1027877;
CC       P38432:COIL; NbExp=3; IntAct=EBI-1642831, EBI-945751;
CC       Q0D2H9:GOLGA8DP; NbExp=3; IntAct=EBI-1642831, EBI-10181276;
CC       Q08AF8:GOLGA8G; NbExp=3; IntAct=EBI-1642831, EBI-10181260;
CC       P43360:MAGEA6; NbExp=3; IntAct=EBI-1642831, EBI-1045155;
CC       Q13077:TRAF1; NbExp=3; IntAct=EBI-1642831, EBI-359224;
CC       Q8IUH5:ZDHHC17; NbExp=2; IntAct=EBI-9090666, EBI-524753;
CC   -!- SUBCELLULAR LOCATION: Apical cell membrane
CC       {ECO:0000269|PubMed:14500724}. Cytoplasm {ECO:0000250}. Membrane
CC       {ECO:0000250}. Cytoplasm, cytoskeleton {ECO:0000250}. Cytoplasm,
CC       cytoskeleton, microtubule organizing center, centrosome
CC       {ECO:0000250}. Note=Found in the soluble fraction, associated with
CC       membranes, and associated with the cytoskeleton and the centrosome
CC       (By similarity). Colocalized with SHANK2 to the apical membrane of
CC       colonic crypt cells. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=12;
CC       Name=4; Synonyms=hPDE4D4;
CC         IsoId=Q08499-1; Sequence=Displayed;
CC       Name=3; Synonyms=hPDE4D3;
CC         IsoId=Q08499-2; Sequence=VSP_004577;
CC         Note=Contains a phosphoserine at position 53. Activated by
CC         phosphorylation at Ser-53. Mutagenesis of Ser-53 abolishes
CC         activation.;
CC       Name=10;
CC         IsoId=Q08499-3; Sequence=VSP_004578;
CC       Name=1; Synonyms=hPDE4D1;
CC         IsoId=Q08499-4; Sequence=VSP_004579;
CC       Name=2; Synonyms=hPDE4D2;
CC         IsoId=Q08499-5; Sequence=VSP_004580;
CC       Name=5; Synonyms=hPDE4D5;
CC         IsoId=Q08499-6; Sequence=VSP_012384;
CC         Note=Contains a phosphoserine at position 59. Contains a
CC         phosphoserine at position 63. {ECO:0000269|PubMed:18669648};
CC       Name=N3; Synonyms=PDE4DN3;
CC         IsoId=Q08499-7; Sequence=VSP_012384, VSP_012391, VSP_012392;
CC         Note=Contains a phosphoserine at position 59. Contains a
CC         phosphoserine at position 63. {ECO:0000269|PubMed:18669648};
CC       Name=6; Synonyms=PDE4D6;
CC         IsoId=Q08499-8; Sequence=VSP_012383, VSP_012393;
CC       Name=8; Synonyms=PDE4D8;
CC         IsoId=Q08499-9; Sequence=VSP_012386, VSP_012389;
CC       Name=9; Synonyms=PDE4D9;
CC         IsoId=Q08499-10; Sequence=VSP_012385, VSP_012390;
CC       Name=7; Synonyms=PDE4D7;
CC         IsoId=Q08499-11; Sequence=VSP_012387, VSP_012388;
CC       Name=12;
CC         IsoId=Q08499-12; Sequence=VSP_012384, VSP_023326, VSP_023327;
CC         Note=Contains a phosphoserine at position 59. Contains a
CC         phosphoserine at position 63. {ECO:0000269|PubMed:18669648};
CC   -!- TISSUE SPECIFICITY: Expressed in colonic epithelial cells (at
CC       protein level). Widespread; most abundant in skeletal muscle.
CC       Isoform 6 is detected in brain. Isoform 8 is detected in brain,
CC       placenta, lung and kidney. Isoform 7 is detected in heart and
CC       skeletal muscle. {ECO:0000269|PubMed:12834813,
CC       ECO:0000269|PubMed:17244609}.
CC   -!- PTM: Long isoforms that share a conserved PKA phosphorylation site
CC       in the N-terminus are activated by PKA through phosphorylation (By
CC       similarity). Isoform 3 and isoform 7 are activated by
CC       phosphorylation (in vitro), but not isoform 6. Isoform N3 and
CC       isoform 12 are phosphorylated on Ser-49, Ser-51, Ser-55 and Ser-
CC       59. {ECO:0000250}.
CC   -!- PTM: Sumoylation of long isoforms by PIAS4 augments their
CC       activation by PKA phosphorylation and represses their inhibition
CC       by ERK phosphorylation. {ECO:0000269|PubMed:20196770}.
CC   -!- DISEASE: Note=Genetic variations in PDE4D might be associated with
CC       susceptibility to stroke. PubMed:17006457 states that association
CC       with stroke has to be considered with caution.
CC   -!- DISEASE: Acrodysostosis 2, with or without hormone resistance
CC       (ACRDYS2) [MIM:614613]: A pleiotropic disorder characterized by
CC       skeletal, endocrine, and neurological abnormalities. Skeletal
CC       features include brachycephaly, midface hypoplasia with a small
CC       upturned nose, brachydactyly, and lumbar spinal stenosis.
CC       Endocrine abnormalities include hypothyroidism and hypogonadism in
CC       males and irregular menses in females. Developmental disability is
CC       a common finding but is variable in severity and can be associated
CC       with significant behavioral problems.
CC       {ECO:0000269|PubMed:22464250, ECO:0000269|PubMed:22464252,
CC       ECO:0000269|PubMed:23033274, ECO:0000269|PubMed:23043190}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the cyclic nucleotide phosphodiesterase
CC       family. PDE4 subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=phosphodiesterase 4D, cAMP-specific
CC       (phosphodiesterase E3 dunce homolog, Drosophila) (PDE4D);
CC       Note=Leiden Open Variation Database (LOVD);
CC       URL="http://www.lovd.nl/PDE4D";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L20970; AAA03592.1; -; mRNA.
DR   EMBL; L20969; AAC00042.1; -; mRNA.
DR   EMBL; U02882; AAC13745.1; -; mRNA.
DR   EMBL; U50157; AAA97890.1; -; mRNA.
DR   EMBL; U50158; AAA97891.1; -; mRNA.
DR   EMBL; U50159; AAA97892.1; -; mRNA.
DR   EMBL; AF012074; AAC00070.1; -; mRNA.
DR   EMBL; AF012073; AAC00069.1; -; mRNA.
DR   EMBL; AJ250854; CAC03757.1; -; mRNA.
DR   EMBL; AF536975; AAN10117.1; -; mRNA.
DR   EMBL; AF536976; AAN10118.1; -; mRNA.
DR   EMBL; AF536977; AAN10119.1; -; mRNA.
DR   EMBL; AY388960; AAQ90404.1; -; mRNA.
DR   EMBL; AY245866; AAP75760.1; -; mRNA.
DR   EMBL; AY245867; AAP75761.1; -; mRNA.
DR   EMBL; BT007398; AAP36062.1; -; mRNA.
DR   EMBL; BC008390; AAH08390.1; -; mRNA.
DR   EMBL; BC036319; AAH36319.1; -; mRNA.
DR   CCDS; CCDS47213.1; -. [Q08499-1]
DR   CCDS; CCDS54858.1; -. [Q08499-2]
DR   CCDS; CCDS54859.1; -. [Q08499-11]
DR   CCDS; CCDS56369.1; -. [Q08499-8]
DR   CCDS; CCDS56370.1; -. [Q08499-5]
DR   CCDS; CCDS56371.1; -. [Q08499-10]
DR   CCDS; CCDS56372.1; -. [Q08499-9]
DR   CCDS; CCDS56373.1; -. [Q08499-6]
DR   PIR; I61358; I61358.
DR   RefSeq; NP_001098101.1; NM_001104631.1. [Q08499-1]
DR   RefSeq; NP_001159371.1; NM_001165899.1. [Q08499-11]
DR   RefSeq; NP_001184147.1; NM_001197218.1. [Q08499-6]
DR   RefSeq; NP_001184148.1; NM_001197219.1. [Q08499-9]
DR   RefSeq; NP_001184149.1; NM_001197220.1. [Q08499-10]
DR   RefSeq; NP_001184150.1; NM_001197221.1. [Q08499-5]
DR   RefSeq; NP_001184151.1; NM_001197222.1.
DR   RefSeq; NP_001184152.1; NM_001197223.1. [Q08499-8]
DR   RefSeq; NP_006194.2; NM_006203.4. [Q08499-2]
DR   RefSeq; XP_005248595.1; XM_005248538.3. [Q08499-2]
DR   RefSeq; XP_011541773.1; XM_011543471.1. [Q08499-11]
DR   RefSeq; XP_011541774.1; XM_011543472.1. [Q08499-11]
DR   RefSeq; XP_011541775.1; XM_011543473.1. [Q08499-11]
DR   UniGene; Hs.117545; -.
DR   PDB; 1E9K; NMR; -; A=-.
DR   PDB; 1MKD; X-ray; 2.90 A; A/B/C/D/E/F/G/H/I/J/K/L=388-715.
DR   PDB; 1OYN; X-ray; 2.00 A; A/B/C/D=381-740.
DR   PDB; 1PTW; X-ray; 2.30 A; A/B/C/D=381-740.
DR   PDB; 1Q9M; X-ray; 2.30 A; A/B/C/D=381-740.
DR   PDB; 1TB7; X-ray; 1.63 A; A/B=388-715.
DR   PDB; 1TBB; X-ray; 1.60 A; A/B=388-715.
DR   PDB; 1XOM; X-ray; 1.55 A; A/B=388-715.
DR   PDB; 1XON; X-ray; 1.72 A; A/B=388-715.
DR   PDB; 1XOQ; X-ray; 1.83 A; A/B=388-715.
DR   PDB; 1XOR; X-ray; 1.54 A; A/B=388-715.
DR   PDB; 1Y2B; X-ray; 1.40 A; A/B=388-715.
DR   PDB; 1Y2C; X-ray; 1.67 A; A/B=388-715.
DR   PDB; 1Y2D; X-ray; 1.70 A; A/B=388-715.
DR   PDB; 1Y2E; X-ray; 2.10 A; A/B=388-715.
DR   PDB; 1Y2K; X-ray; 1.36 A; A/B=388-715.
DR   PDB; 1ZKN; X-ray; 2.10 A; A/B/C/D=381-714.
DR   PDB; 2FM0; X-ray; 2.00 A; A/B/C/D=381-741.
DR   PDB; 2FM5; X-ray; 2.03 A; A/B/C/D=381-741.
DR   PDB; 2PW3; X-ray; 1.56 A; A/B=388-714.
DR   PDB; 2QYN; X-ray; 1.57 A; A/B=388-715.
DR   PDB; 3G4G; X-ray; 2.30 A; A/B/C/D=299-347, A/B/C/D=360-714.
DR   PDB; 3G4I; X-ray; 1.90 A; A/B/C/D=380-753.
DR   PDB; 3G4K; X-ray; 1.95 A; A/B/C/D=380-753.
DR   PDB; 3G4L; X-ray; 2.50 A; A/B/C/D=380-753.
DR   PDB; 3G58; X-ray; 2.05 A; A/B/C/D=380-753.
DR   PDB; 3IAD; X-ray; 2.65 A; A/B/C/D=326-339, A/B/C/D=380-714.
DR   PDB; 3IAK; X-ray; 2.80 A; A=388-715.
DR   PDB; 3K4S; X-ray; 2.05 A; A=388-715.
DR   PDB; 3SL3; X-ray; 2.10 A; A/B/C/D=381-741.
DR   PDB; 3SL4; X-ray; 1.90 A; A/B/C/D=381-741.
DR   PDB; 3SL5; X-ray; 2.65 A; A/B/C/D=381-714.
DR   PDB; 3SL6; X-ray; 2.44 A; A/B/C/D=381-741.
DR   PDB; 3SL8; X-ray; 2.60 A; A/B/C/D=381-741.
DR   PDB; 3V9B; X-ray; 2.10 A; A/B/C/D=381-740.
DR   PDB; 4OGB; X-ray; 2.03 A; A/B/C/D=381-741.
DR   PDB; 4W1O; X-ray; 2.20 A; A/B/C/D=381-739.
DR   PDB; 4WCU; X-ray; 2.35 A; A/B/C/D=381-739.
DR   PDBsum; 1E9K; -.
DR   PDBsum; 1MKD; -.
DR   PDBsum; 1OYN; -.
DR   PDBsum; 1PTW; -.
DR   PDBsum; 1Q9M; -.
DR   PDBsum; 1TB7; -.
DR   PDBsum; 1TBB; -.
DR   PDBsum; 1XOM; -.
DR   PDBsum; 1XON; -.
DR   PDBsum; 1XOQ; -.
DR   PDBsum; 1XOR; -.
DR   PDBsum; 1Y2B; -.
DR   PDBsum; 1Y2C; -.
DR   PDBsum; 1Y2D; -.
DR   PDBsum; 1Y2E; -.
DR   PDBsum; 1Y2K; -.
DR   PDBsum; 1ZKN; -.
DR   PDBsum; 2FM0; -.
DR   PDBsum; 2FM5; -.
DR   PDBsum; 2PW3; -.
DR   PDBsum; 2QYN; -.
DR   PDBsum; 3G4G; -.
DR   PDBsum; 3G4I; -.
DR   PDBsum; 3G4K; -.
DR   PDBsum; 3G4L; -.
DR   PDBsum; 3G58; -.
DR   PDBsum; 3IAD; -.
DR   PDBsum; 3IAK; -.
DR   PDBsum; 3K4S; -.
DR   PDBsum; 3SL3; -.
DR   PDBsum; 3SL4; -.
DR   PDBsum; 3SL5; -.
DR   PDBsum; 3SL6; -.
DR   PDBsum; 3SL8; -.
DR   PDBsum; 3V9B; -.
DR   PDBsum; 4OGB; -.
DR   PDBsum; 4W1O; -.
DR   PDBsum; 4WCU; -.
DR   ProteinModelPortal; Q08499; -.
DR   SMR; Q08499; 327-739.
DR   BioGrid; 111170; 37.
DR   DIP; DIP-29709N; -.
DR   DIP; DIP-41115N; -.
DR   IntAct; Q08499; 15.
DR   MINT; MINT-92262; -.
DR   STRING; 9606.ENSP00000345502; -.
DR   BindingDB; Q08499; -.
DR   ChEMBL; CHEMBL2363066; -.
DR   DrugBank; DB00131; Adenosine monophosphate.
DR   DrugBank; DB00201; Caffeine.
DR   DrugBank; DB00651; Dyphylline.
DR   DrugBank; DB05266; Ibudilast.
DR   DrugBank; DB01088; Iloprost.
DR   DrugBank; DB00920; Ketotifen.
DR   DrugBank; DB01656; Roflumilast.
DR   GuidetoPHARMACOLOGY; 1303; -.
DR   PhosphoSite; Q08499; -.
DR   BioMuta; PDE4D; -.
DR   DMDM; 12644392; -.
DR   MaxQB; Q08499; -.
DR   PaxDb; Q08499; -.
DR   PRIDE; Q08499; -.
DR   DNASU; 5144; -.
DR   Ensembl; ENST00000309641; ENSP00000308485; ENSG00000113448. [Q08499-7]
DR   Ensembl; ENST00000317118; ENSP00000321739; ENSG00000113448. [Q08499-8]
DR   Ensembl; ENST00000340635; ENSP00000345502; ENSG00000113448.
DR   Ensembl; ENST00000358923; ENSP00000351800; ENSG00000113448. [Q08499-5]
DR   Ensembl; ENST00000360047; ENSP00000353152; ENSG00000113448. [Q08499-2]
DR   Ensembl; ENST00000405755; ENSP00000384806; ENSG00000113448. [Q08499-9]
DR   Ensembl; ENST00000502484; ENSP00000423094; ENSG00000113448. [Q08499-11]
DR   Ensembl; ENST00000502575; ENSP00000425917; ENSG00000113448. [Q08499-12]
DR   Ensembl; ENST00000503258; ENSP00000425605; ENSG00000113448. [Q08499-10]
DR   Ensembl; ENST00000507116; ENSP00000424852; ENSG00000113448. [Q08499-6]
DR   GeneID; 5144; -.
DR   KEGG; hsa:5144; -.
DR   UCSC; uc003jrs.2; human. [Q08499-8]
DR   UCSC; uc003jrt.2; human. [Q08499-1]
DR   UCSC; uc003jru.3; human. [Q08499-4]
DR   UCSC; uc003jrv.2; human. [Q08499-10]
DR   UCSC; uc003jrw.2; human. [Q08499-9]
DR   UCSC; uc003jrz.3; human. [Q08499-6]
DR   UCSC; uc003jsb.3; human. [Q08499-11]
DR   UCSC; uc003jsc.3; human. [Q08499-12]
DR   CTD; 5144; -.
DR   GeneCards; GC05M058302; -.
DR   HGNC; HGNC:8783; PDE4D.
DR   HPA; HPA045895; -.
DR   MIM; 600129; gene.
DR   MIM; 614613; phenotype.
DR   neXtProt; NX_Q08499; -.
DR   Orphanet; 950; Acrodysostosis.
DR   Orphanet; 280651; Acrodysostosis with multiple hormone resistance.
DR   PharmGKB; PA33130; -.
DR   eggNOG; NOG122287; -.
DR   GeneTree; ENSGT00760000118889; -.
DR   HOVERGEN; HBG108239; -.
DR   KO; K13293; -.
DR   OMA; PLDPMAS; -.
DR   OrthoDB; EOG7HQNBC; -.
DR   PhylomeDB; Q08499; -.
DR   TreeFam; TF314638; -.
DR   BRENDA; 3.1.4.53; 2681.
DR   Reactome; REACT_15334; DARPP-32 events.
DR   Reactome; REACT_19327; G alpha (s) signalling events.
DR   SignaLink; Q08499; -.
DR   UniPathway; UPA00762; UER00747.
DR   ChiTaRS; PDE4D; human.
DR   EvolutionaryTrace; Q08499; -.
DR   GeneWiki; PDE4D; -.
DR   GenomeRNAi; 5144; -.
DR   NextBio; 19846; -.
DR   PRO; PR:Q08499; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; Q08499; -.
DR   ExpressionAtlas; Q08499; baseline and differential.
DR   Genevisible; Q08499; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0034704; C:calcium channel complex; IDA:BHF-UCL.
DR   GO; GO:0005813; C:centrosome; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; IDA:BHF-UCL.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:Ensembl.
DR   GO; GO:0016020; C:membrane; IDA:BHF-UCL.
DR   GO; GO:0030016; C:myofibril; IEA:Ensembl.
DR   GO; GO:0005891; C:voltage-gated calcium channel complex; IEA:Ensembl.
DR   GO; GO:0004115; F:3',5'-cyclic-AMP phosphodiesterase activity; IDA:BHF-UCL.
DR   GO; GO:0004114; F:3',5'-cyclic-nucleotide phosphodiesterase activity; NAS:UniProtKB.
DR   GO; GO:0051117; F:ATPase binding; IPI:BHF-UCL.
DR   GO; GO:0031698; F:beta-2 adrenergic receptor binding; ISS:BHF-UCL.
DR   GO; GO:0030552; F:cAMP binding; IDA:BHF-UCL.
DR   GO; GO:0008144; F:drug binding; IPI:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; ISS:BHF-UCL.
DR   GO; GO:0044325; F:ion channel binding; IPI:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0097110; F:scaffold protein binding; IPI:BHF-UCL.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:BHF-UCL.
DR   GO; GO:0071875; P:adrenergic receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0086024; P:adrenergic receptor signaling pathway involved in positive regulation of heart rate; IC:BHF-UCL.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0006198; P:cAMP catabolic process; IDA:BHF-UCL.
DR   GO; GO:0019933; P:cAMP-mediated signaling; NAS:BHF-UCL.
DR   GO; GO:0043623; P:cellular protein complex assembly; IEA:Ensembl.
DR   GO; GO:0071320; P:cellular response to cAMP; IDA:BHF-UCL.
DR   GO; GO:0071872; P:cellular response to epinephrine stimulus; IDA:BHF-UCL.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0061028; P:establishment of endothelial barrier; ISS:UniProtKB.
DR   GO; GO:0030324; P:lung development; IEA:Ensembl.
DR   GO; GO:0007613; P:memory; IEA:Ensembl.
DR   GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0045822; P:negative regulation of heart contraction; ISS:BHF-UCL.
DR   GO; GO:0033137; P:negative regulation of peptidyl-serine phosphorylation; ISS:BHF-UCL.
DR   GO; GO:1901898; P:negative regulation of relaxation of cardiac muscle; ISS:BHF-UCL.
DR   GO; GO:0030593; P:neutrophil chemotaxis; IEA:Ensembl.
DR   GO; GO:0032729; P:positive regulation of interferon-gamma production; IMP:BHF-UCL.
DR   GO; GO:0032743; P:positive regulation of interleukin-2 production; IMP:BHF-UCL.
DR   GO; GO:0032754; P:positive regulation of interleukin-5 production; IMP:BHF-UCL.
DR   GO; GO:0014911; P:positive regulation of smooth muscle cell migration; IEA:Ensembl.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0030814; P:regulation of cAMP metabolic process; IEA:Ensembl.
DR   GO; GO:0086004; P:regulation of cardiac muscle cell contraction; ISS:BHF-UCL.
DR   GO; GO:1901844; P:regulation of cell communication by electrical coupling involved in cardiac conduction; IC:BHF-UCL.
DR   GO; GO:0008277; P:regulation of G-protein coupled receptor protein signaling pathway; IEA:Ensembl.
DR   GO; GO:0002027; P:regulation of heart rate; ISS:BHF-UCL.
DR   GO; GO:0010738; P:regulation of protein kinase A signaling; IEA:Ensembl.
DR   GO; GO:0010469; P:regulation of receptor activity; ISS:BHF-UCL.
DR   GO; GO:0010880; P:regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum; ISS:BHF-UCL.
DR   GO; GO:0060314; P:regulation of ryanodine-sensitive calcium-release channel activity; ISS:BHF-UCL.
DR   GO; GO:0006939; P:smooth muscle contraction; IEA:Ensembl.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; IMP:BHF-UCL.
DR   Gene3D; 1.10.1300.10; -; 1.
DR   InterPro; IPR003607; HD/PDEase_dom.
DR   InterPro; IPR023088; PDEase.
DR   InterPro; IPR002073; PDEase_catalytic_dom.
DR   InterPro; IPR023174; PDEase_CS.
DR   Pfam; PF00233; PDEase_I; 1.
DR   PRINTS; PR00387; PDIESTERASE1.
DR   SMART; SM00471; HDc; 1.
DR   PROSITE; PS00126; PDEASE_I; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; cAMP; Cell membrane;
KW   Complete proteome; Cytoplasm; Cytoskeleton; Disease mutation;
KW   Hydrolase; Isopeptide bond; Membrane; Metal-binding; Phosphoprotein;
KW   Reference proteome; Ubl conjugation.
FT   CHAIN         1    809       cAMP-specific 3',5'-cyclic
FT                                phosphodiesterase 4D.
FT                                /FTId=PRO_0000198814.
FT   NP_BIND     462    466       cAMP. {ECO:0000269|PubMed:14609333,
FT                                ECO:0000269|PubMed:17582435}.
FT   COMPBIAS     42     88       Pro-rich.
FT   ACT_SITE    462    462       Proton donor. {ECO:0000250}.
FT   METAL       466    466       Divalent metal cation 1.
FT   METAL       502    502       Divalent metal cation 1.
FT   METAL       503    503       Divalent metal cation 1.
FT   METAL       503    503       Divalent metal cation 2.
FT   METAL       620    620       Divalent metal cation 1.
FT   BINDING     503    503       cAMP. {ECO:0000269|PubMed:14609333,
FT                                ECO:0000269|PubMed:17582435}.
FT   BINDING     620    620       cAMP. {ECO:0000269|PubMed:14609333,
FT                                ECO:0000269|PubMed:17582435}.
FT   BINDING     671    671       cAMP. {ECO:0000269|PubMed:14609333,
FT                                ECO:0000269|PubMed:17582435}.
FT   SITE        623    623       Binds AMP, but not cAMP.
FT   MOD_RES     299    299       Phosphoserine.
FT                                {ECO:0000269|PubMed:21406692}.
FT   MOD_RES     301    301       Phosphoserine.
FT                                {ECO:0000269|PubMed:21406692}.
FT   CROSSLNK    387    387       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT   VAR_SEQ       1    302       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:8797812,
FT                                ECO:0000303|PubMed:9371713}.
FT                                /FTId=VSP_004580.
FT   VAR_SEQ       1    291       Missing (in isoform 6).
FT                                {ECO:0000303|PubMed:12834813,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_012383.
FT   VAR_SEQ       1    269       MEAEGSSAPARAGSGEGSDSAGGATLKAPKHLWRHEQHHQY
FT                                PLRQPQFRLLHPHHHLPPPPPPSPQPQPQCPLQPPPPPPLP
FT                                PPPPPPGAARGRYASSGATGRVRHRGYSDTERYLYCRAMDR
FT                                TSYAVETGHRPGLKKSRMSWPSSFQGLRRFDVDNGTSAGRS
FT                                PLDPMTSPGSGLILQANFVHSQRRESFLYRSDSDYDLSPKS
FT                                MSRNSSIASDIHGDDLIVTPFAQVLASLRTVRNNFAALTNL
FT                                QDRAPSKRSPMCNQPSINKATIT -> MKEQPSCAGTGHPM
FT                                AGYGRMAPFELASGPVKRLRTESPFPCLFA (in
FT                                isoform 1). {ECO:0000303|PubMed:8797812,
FT                                ECO:0000303|PubMed:9371713}.
FT                                /FTId=VSP_004579.
FT   VAR_SEQ       1    205       Missing (in isoform 10).
FT                                {ECO:0000303|PubMed:8125310,
FT                                ECO:0000303|PubMed:9371713}.
FT                                /FTId=VSP_004578.
FT   VAR_SEQ       1    152       MEAEGSSAPARAGSGEGSDSAGGATLKAPKHLWRHEQHHQY
FT                                PLRQPQFRLLHPHHHLPPPPPPSPQPQPQCPLQPPPPPPLP
FT                                PPPPPPGAARGRYASSGATGRVRHRGYSDTERYLYCRAMDR
FT                                TSYAVETGHRPGLKKSRMSWPSSFQGLRR -> MMHVNNFP
FT                                FRRHSWIC (in isoform 3).
FT                                {ECO:0000303|PubMed:8413254,
FT                                ECO:0000303|PubMed:9371713}.
FT                                /FTId=VSP_004577.
FT   VAR_SEQ       1    152       MEAEGSSAPARAGSGEGSDSAGGATLKAPKHLWRHEQHHQY
FT                                PLRQPQFRLLHPHHHLPPPPPPSPQPQPQCPLQPPPPPPLP
FT                                PPPPPPGAARGRYASSGATGRVRHRGYSDTERYLYCRAMDR
FT                                TSYAVETGHRPGLKKSRMSWPSSFQGLRR -> MAQQTSPD
FT                                TLTVPEVDNPHCPNPWLNEDLVKSLRENLLQHEKSKTARKS
FT                                VSPKLSPVISPRNSPRLLRRMLLSSNIPKQRRFTVAHTC
FT                                (in isoform 5, isoform N3 and isoform
FT                                12). {ECO:0000303|PubMed:10913353,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:9371713,
FT                                ECO:0000303|Ref.9}.
FT                                /FTId=VSP_012384.
FT   VAR_SEQ       1    130       Missing (in isoform 9).
FT                                {ECO:0000303|PubMed:12834813,
FT                                ECO:0000303|PubMed:14517540}.
FT                                /FTId=VSP_012385.
FT   VAR_SEQ       1    122       Missing (in isoform 8).
FT                                {ECO:0000303|PubMed:12834813}.
FT                                /FTId=VSP_012386.
FT   VAR_SEQ       1     61       Missing (in isoform 7).
FT                                {ECO:0000303|PubMed:12834813,
FT                                ECO:0000303|PubMed:14517540}.
FT                                /FTId=VSP_012387.
FT   VAR_SEQ      62    152       PPSPQPQPQCPLQPPPPPPLPPPPPPPGAARGRYASSGATG
FT                                RVRHRGYSDTERYLYCRAMDRTSYAVETGHRPGLKKSRMSW
FT                                PSSFQGLRR -> MKRNTCDLLSRSKSASEETLHSSNEEED
FT                                PFRGMEPYLVRRLSCRNIQLPPLAFRQLEQADLKSESENIQ
FT                                RPTSLPLKILPLIAITSAESSG (in isoform 7).
FT                                {ECO:0000303|PubMed:12834813,
FT                                ECO:0000303|PubMed:14517540}.
FT                                /FTId=VSP_012388.
FT   VAR_SEQ     123    152       RTSYAVETGHRPGLKKSRMSWPSSFQGLRR -> MAFVWDP
FT                                LGATVPGPSTRAKSRLRFSKSYS (in isoform 8).
FT                                {ECO:0000303|PubMed:12834813}.
FT                                /FTId=VSP_012389.
FT   VAR_SEQ     131    152       GHRPGLKKSRMSWPSSFQGLRR -> MSIIMKPRSRSTSSL
FT                                RTAEAVC (in isoform 9).
FT                                {ECO:0000303|PubMed:12834813,
FT                                ECO:0000303|PubMed:14517540}.
FT                                /FTId=VSP_012390.
FT   VAR_SEQ     270    283       EEAYQKLASETLEE -> GSWMELNPYTLLDM (in
FT                                isoform 12).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|Ref.9}.
FT                                /FTId=VSP_023326.
FT   VAR_SEQ     270    279       EEAYQKLASE -> GLYNGIIAFL (in isoform N3).
FT                                {ECO:0000303|PubMed:10913353}.
FT                                /FTId=VSP_012391.
FT   VAR_SEQ     280    809       Missing (in isoform N3).
FT                                {ECO:0000303|PubMed:10913353}.
FT                                /FTId=VSP_012392.
FT   VAR_SEQ     284    809       Missing (in isoform 12).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|Ref.9}.
FT                                /FTId=VSP_023327.
FT   VAR_SEQ     292    306       ETLQTRHSVSEMASN -> MPEANYLLSVSWGYI (in
FT                                isoform 6). {ECO:0000303|PubMed:12834813,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_012393.
FT   VARIANT     190    190       S -> A (in ACRDYS2).
FT                                {ECO:0000269|PubMed:22464250}.
FT                                /FTId=VAR_068242.
FT   VARIANT     225    225       P -> T (in ACRDYS2).
FT                                {ECO:0000269|PubMed:22464250,
FT                                ECO:0000269|PubMed:23033274}.
FT                                /FTId=VAR_068243.
FT   VARIANT     226    226       F -> S (in ACRDYS2).
FT                                {ECO:0000269|PubMed:22464250}.
FT                                /FTId=VAR_068244.
FT   VARIANT     227    227       A -> S (in ACRDYS2).
FT                                {ECO:0000269|PubMed:23043190}.
FT                                /FTId=VAR_069448.
FT   VARIANT     228    228       Q -> E (in ACRDYS2).
FT                                {ECO:0000269|PubMed:22464252}.
FT                                /FTId=VAR_069449.
FT   VARIANT     301    301       S -> T (in ACRDYS2).
FT                                {ECO:0000269|PubMed:23033274}.
FT                                /FTId=VAR_069450.
FT   VARIANT     304    304       A -> V (in ACRDYS2).
FT                                {ECO:0000269|PubMed:23033274}.
FT                                /FTId=VAR_069451.
FT   VARIANT     329    329       V -> A (in ACRDYS2).
FT                                {ECO:0000269|PubMed:23033274}.
FT                                /FTId=VAR_069452.
FT   VARIANT     587    587       T -> P (in ACRDYS2).
FT                                {ECO:0000269|PubMed:22464250}.
FT                                /FTId=VAR_068245.
FT   VARIANT     590    590       E -> A (in ACRDYS2).
FT                                {ECO:0000269|PubMed:22464252,
FT                                ECO:0000269|PubMed:23043190}.
FT                                /FTId=VAR_069453.
FT   VARIANT     673    673       G -> D (in ACRDYS2).
FT                                {ECO:0000269|PubMed:22464252}.
FT                                /FTId=VAR_069454.
FT   VARIANT     678    678       I -> T (in ACRDYS2).
FT                                {ECO:0000269|PubMed:23033274}.
FT                                /FTId=VAR_069455.
FT   MUTAGEN     503    503       D->N: Abolishes catalytic activity.
FT   MUTAGEN     527    527       D->R: Abolishes homodimerization.
FT                                {ECO:0000269|PubMed:12387865}.
FT   MUTAGEN     563    563       R->D: Abolishes homodimerization.
FT                                {ECO:0000269|PubMed:12387865}.
FT   CONFLICT    510    510       S -> F (in Ref. 10; AAH36319).
FT                                {ECO:0000305}.
FT   CONFLICT    549    549       D -> G (in Ref. 6; AAN10119).
FT                                {ECO:0000305}.
FT   CONFLICT    644    644       R -> P (in Ref. 2). {ECO:0000305}.
FT   CONFLICT    769    769       C -> R (in Ref. 3; AAA97890/AAA97891/
FT                                AAA97892). {ECO:0000305}.
FT   HELIX       328    336       {ECO:0000244|PDB:3G4G}.
FT   STRAND      383    386       {ECO:0000244|PDB:1OYN}.
FT   HELIX       389    397       {ECO:0000244|PDB:1Y2K}.
FT   HELIX       398    400       {ECO:0000244|PDB:1Y2K}.
FT   HELIX       408    414       {ECO:0000244|PDB:1Y2K}.
FT   HELIX       419    430       {ECO:0000244|PDB:1Y2K}.
FT   HELIX       433    436       {ECO:0000244|PDB:1Y2K}.
FT   HELIX       441    453       {ECO:0000244|PDB:1Y2K}.
FT   STRAND      460    463       {ECO:0000244|PDB:1Y2K}.
FT   HELIX       464    478       {ECO:0000244|PDB:1Y2K}.
FT   HELIX       481    483       {ECO:0000244|PDB:1Y2K}.
FT   TURN        484    486       {ECO:0000244|PDB:1Y2K}.
FT   HELIX       489    501       {ECO:0000244|PDB:1Y2K}.
FT   TURN        502    505       {ECO:0000244|PDB:1Y2K}.
FT   HELIX       511    516       {ECO:0000244|PDB:1Y2K}.
FT   HELIX       520    525       {ECO:0000244|PDB:1Y2K}.
FT   HELIX       530    541       {ECO:0000244|PDB:1Y2K}.
FT   HELIX       542    544       {ECO:0000244|PDB:1Y2K}.
FT   TURN        545    547       {ECO:0000244|PDB:3IAK}.
FT   TURN        550    553       {ECO:0000244|PDB:1Y2K}.
FT   HELIX       556    571       {ECO:0000244|PDB:1Y2K}.
FT   HELIX       575    577       {ECO:0000244|PDB:1Y2K}.
FT   HELIX       578    590       {ECO:0000244|PDB:1Y2K}.
FT   STRAND      598    600       {ECO:0000244|PDB:2QYN}.
FT   HELIX       605    620       {ECO:0000244|PDB:1Y2K}.
FT   HELIX       623    625       {ECO:0000244|PDB:1Y2K}.
FT   HELIX       628    652       {ECO:0000244|PDB:1Y2K}.
FT   TURN        658    660       {ECO:0000244|PDB:3SL3}.
FT   STRAND      662    664       {ECO:0000244|PDB:4OGB}.
FT   HELIX       667    677       {ECO:0000244|PDB:1Y2K}.
FT   HELIX       679    689       {ECO:0000244|PDB:1Y2K}.
FT   TURN        690    694       {ECO:0000244|PDB:1Y2K}.
FT   HELIX       695    710       {ECO:0000244|PDB:1Y2K}.
FT   HELIX       730    734       {ECO:0000244|PDB:3G58}.
FT   TURN        735    738       {ECO:0000244|PDB:3G58}.
SQ   SEQUENCE   809 AA;  91115 MW;  7A4773DD3A044F57 CRC64;
     MEAEGSSAPA RAGSGEGSDS AGGATLKAPK HLWRHEQHHQ YPLRQPQFRL LHPHHHLPPP
     PPPSPQPQPQ CPLQPPPPPP LPPPPPPPGA ARGRYASSGA TGRVRHRGYS DTERYLYCRA
     MDRTSYAVET GHRPGLKKSR MSWPSSFQGL RRFDVDNGTS AGRSPLDPMT SPGSGLILQA
     NFVHSQRRES FLYRSDSDYD LSPKSMSRNS SIASDIHGDD LIVTPFAQVL ASLRTVRNNF
     AALTNLQDRA PSKRSPMCNQ PSINKATITE EAYQKLASET LEELDWCLDQ LETLQTRHSV
     SEMASNKFKR MLNRELTHLS EMSRSGNQVS EFISNTFLDK QHEVEIPSPT QKEKEKKKRP
     MSQISGVKKL MHSSSLTNSS IPRFGVKTEQ EDVLAKELED VNKWGLHVFR IAELSGNRPL
     TVIMHTIFQE RDLLKTFKIP VDTLITYLMT LEDHYHADVA YHNNIHAADV VQSTHVLLST
     PALEAVFTDL EILAAIFASA IHDVDHPGVS NQFLINTNSE LALMYNDSSV LENHHLAVGF
     KLLQEENCDI FQNLTKKQRQ SLRKMVIDIV LATDMSKHMN LLADLKTMVE TKKVTSSGVL
     LLDNYSDRIQ VLQNMVHCAD LSNPTKPLQL YRQWTDRIME EFFRQGDRER ERGMEISPMC
     DKHNASVEKS QVGFIDYIVH PLWETWADLV HPDAQDILDT LEDNREWYQS TIPQSPSPAP
     DDPEEGRQGQ TEKFQFELTL EEDGESDTEK DSGSQVEEDT SCSDSKTLCT QDSESTEIPL
     DEQVEEEAVG EEEESQPEAC VIDDRSPDT
//
